You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCarbamazepine
Accession NumberDB00564  (APRD00337)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAn anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. [PubChem]
Structure
Thumb
Synonyms
5-Carbamoyl-5H-dibenz(b,f)azepine
5-Carbamoyl-5H-dibenz[b,F]azepine
5-Carbamoyl-5H-dibenzo(b,F)azepine
5-Carbamyl-5H-dibenzo(b,F)azepine
5H-Dibenz(b,F)azepine-5-carboxamide
Carbamazepen
Carbamazepin
Carbamazepina
Carbamazépine
Carbamazepinum
CBZ
External Identifiers
  • G 32 883
  • SPD417
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bio-carbamazepineTablet200 mgOralBiomed Pharma2003-08-202010-03-16Canada
CarbamazepineCapsule, extended release100 mg/1OralPrasco Laboratories2011-12-15Not applicableUs
CarbamazepineCapsule, extended release200 mg/1OralPrasco Laboratories2011-12-15Not applicableUs
CarbamazepineTablet, extended release200 mg/1OralKAISER FOUNDATION HOSPITALS2009-10-28Not applicableUs
CarbamazepineCapsule, extended release300 mg/1OralPrasco Laboratories2011-12-15Not applicableUs
CarbamazepineCapsule, extended release300 mg/1OralAvera Mc Kennan Hospital2015-06-08Not applicableUs
Carbamazepine 200 Tab 200mgTablet200 mgOralPro Doc Limitee1982-12-312013-07-15Canada
Carbamazepine 200mg TabletsTablet200 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Carbamazepine CRTablet, extended release200 mgOralPro Doc Limitee2013-11-21Not applicableCanada
Carbamazepine CRTablet, extended release400 mgOralPro Doc Limitee2013-11-21Not applicableCanada
Carbamazepine ERTablet, extended release200 mg/1OralSandoz Inc1996-03-25Not applicableUs
Carbamazepine ERTablet, extended release400 mg/1OralAmerican Health Packaging2013-06-24Not applicableUs
Carbamazepine ERTablet, extended release400 mg/1OralSandoz Inc1996-03-25Not applicableUs
Carbamazepine ERTablet, extended release100 mg/1OralREMEDYREPACK INC.2016-09-27Not applicableUs
Carbamazepine ERTablet, extended release400 mg/1OralPhysicians Total Care, Inc.2009-10-16Not applicableUs
Carbamazepine ERTablet, extended release100 mg/1OralSandoz Inc1996-03-25Not applicableUs
Carbamazepine ERTablet, extended release200 mg/1OralAmerican Health Packaging2013-06-24Not applicableUs
Carbamazepine-CR -(200mg)Tablet, extended release200 mgOralPro Doc Limitee2001-05-222009-07-23Canada
Carbamazepine-CR -(400mg)Tablet, extended release400 mgOralPro Doc Limitee2001-05-222009-07-23Canada
Carbamazepineer ERTablet, extended release400 mg/1OralREMEDYREPACK INC.2016-01-07Not applicableUs
CarbatrolCapsule, extended release300 mg/1OralShire US Manufacturing Inc.1997-09-30Not applicableUs
CarbatrolCapsule, extended release300 mg/1OralPhysicians Total Care, Inc.2009-10-15Not applicableUs
CarbatrolCapsule, extended release100 mg/1OralShire US Manufacturing Inc.1999-12-22Not applicableUs
CarbatrolCapsule, extended release200 mg/1OralShire US Manufacturing Inc.1997-09-30Not applicableUs
CarnexivInjection, powder, for solution10 mg/mLIntravenousLundbeck LLC2014-10-21Not applicableUs
Dom-carbamazepineTablet200 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-carbamazepine CRTablet, extended release200 mgOralDominion Pharmacal1998-09-17Not applicableCanada
Dom-carbamazepine CRTablet, extended release400 mgOralDominion Pharmacal1998-09-17Not applicableCanada
EquetroCapsule, extended release100 mg/1OralValidus Pharmaceuticals LLC2004-12-10Not applicableUs
EquetroCapsule, extended release200 mg/1OralValidus Pharmaceuticals LLC2004-12-10Not applicableUs
EquetroCapsule, extended release300 mg/1OralValidus Pharmaceuticals LLC2004-12-10Not applicableUs
MazepineTablet200 mgOralBiomed Pharma1981-12-31Not applicableCanada
Mylan-carbamazepine CRTablet, extended release400 mgOralMylan Pharmaceuticals Ulc2000-03-16Not applicableCanada
Mylan-carbamazepine CRTablet, extended release200 mgOralMylan Pharmaceuticals Ulc2000-03-16Not applicableCanada
Nu-carbamazepine Tab 200mgTablet200 mgOralNu Pharm Inc1993-12-312012-09-04Canada
PHL-carbamazepine CRTablet, extended release200 mgOralPharmel Inc1998-09-032009-10-26Canada
PHL-carbamazepine CRTablet, extended release400 mgOralPharmel Inc1998-09-032009-10-26Canada
PMS-carbamazepineTablet, chewable200 mgOralPharmascience Inc2002-08-13Not applicableCanada
PMS-carbamazepineTablet200 mgOralPharmascience Inc1986-12-31Not applicableCanada
PMS-carbamazepineTablet, chewable100 mgOralPharmascience Inc2002-08-13Not applicableCanada
PMS-carbamazepineTablet200 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-carbamazepine CRTablet, extended release200 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-carbamazepine CRTablet, extended release400 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-carbamazepine-CRTablet, extended release400 mgOralPharmascience Inc1998-05-28Not applicableCanada
PMS-carbamazepine-CRTablet, extended release200 mgOralPharmascience Inc1998-05-28Not applicableCanada
Sandoz-carbamazepine ChewtabsTablet200 mgOralSandoz Canada Incorporated2006-02-02Not applicableCanada
Sandoz-carbamazepine ChewtabsTablet100 mgOralSandoz Canada Incorporated2006-02-02Not applicableCanada
Sandoz-carbamazepine CRTablet, extended release200 mgOralSandoz Canada Incorporated2006-02-02Not applicableCanada
Sandoz-carbamazepine CRTablet, extended release400 mgOralSandoz Canada Incorporated2006-02-02Not applicableCanada
Taro-carbamazepineSuspension100 mgOralTaro Pharmaceuticals Inc2011-10-07Not applicableCanada
Taro-carbamazepineTablet200 mgOralTaro Pharmaceuticals Inc2014-05-14Not applicableCanada
Taro-carbamazepine Chewable Tablets 100mgTablet, chewable100 mgOralTaro Pharmaceuticals Inc2002-04-19Not applicableCanada
Taro-carbamazepine Chewable Tablets 200mgTablet, chewable200 mgOralTaro Pharmaceuticals Inc2002-04-19Not applicableCanada
Taro-carbamazepine CR 200 mgTablet, extended release200 mgOralTaro Pharmaceuticals Inc1998-05-27Not applicableCanada
Taro-carbamazepine CR 400 mgTablet, extended release400 mgOralTaro Pharmaceuticals Inc1998-05-27Not applicableCanada
Taro-carbamazepine Tab 200mgTablet200 mgOralTaro Pharmaceuticals Inc1994-12-312001-08-21Canada
TegretolSuspension100 mg/5mLOralNovartis Pharmaceuticals Corporation1987-12-18Not applicableUs
TegretolTablet200 mg/1OralREMEDYREPACK INC.2015-10-19Not applicableUs
TegretolTablet200 mg/1OralNovartis Pharmaceuticals Corporation1968-03-11Not applicableUs
Tegretol - Sus 100mg/5mlSuspension100 mgOralNovartis Pharmaceuticals Canada Inc1996-12-31Not applicableCanada
Tegretol 200mgTablet200 mgOralNovartis Pharmaceuticals Canada Inc1969-12-31Not applicableCanada
Tegretol Chewtabs 100mgTablet100 mgOralNovartis Pharmaceuticals Canada Inc1985-12-31Not applicableCanada
Tegretol Chewtabs 200mgTablet200 mgOralNovartis Pharmaceuticals Canada Inc1985-12-31Not applicableCanada
Tegretol CR Tab 200mgTablet, extended release200 mgOralNovartis Pharmaceuticals Canada Inc1988-12-31Not applicableCanada
Tegretol CR Tab 400mgTablet, extended release400 mgOralNovartis Pharmaceuticals Canada Inc1988-12-31Not applicableCanada
Tegretol XRTablet, extended release400 mg/1OralNovartis Pharmaceuticals Corporation1996-03-25Not applicableUs
Tegretol XRTablet, extended release100 mg/1OralNovartis Pharmaceuticals Corporation1996-03-25Not applicableUs
Tegretol XRTablet, extended release100 mg/1OralAvera Mc Kennan Hospital2015-05-14Not applicableUs
Tegretol XRTablet, extended release200 mg/1OralNovartis Pharmaceuticals Corporation1996-03-25Not applicableUs
Tegretolxr XRTablet, extended release100 mg/1OralREMEDYREPACK INC.2015-10-19Not applicableUs
Teva-carbamazepineTablet200 mgOralTeva Canada Limited1988-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Carbamazepine Tab 200mgTablet200 mgOralApotex Inc1980-12-31Not applicableCanada
Apo-carbamazepine CRTablet, extended release200 mgOralApotex IncNot applicableNot applicableCanada
Apo-carbamazepine CRTablet, extended release400 mgOralApotex IncNot applicableNot applicableCanada
CarbamazepineTablet200 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-03-07Not applicableUs
CarbamazepineCapsule, extended release200 mg/1OralGolden State Medical Supply, Inc.2011-05-20Not applicableUs
CarbamazepineTablet200 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1990-09-30Not applicableUs
CarbamazepineTablet, chewable200 mg/1OralPreferred Pharmaceuticals, Inc2012-04-23Not applicableUs
CarbamazepineTablet200 mg/1OralREMEDYREPACK INC.2011-05-16Not applicableUs
CarbamazepineTablet100 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
CarbamazepineTablet200 mg/1OralMylan Institutional Inc.1995-09-28Not applicableUs
CarbamazepineTablet, chewable100 mg/1OralGolden State Medical Supply, Inc.2000-10-24Not applicableUs
CarbamazepineTablet, extended release200 mg/1OralCardinal Health2009-03-31Not applicableUs
CarbamazepineCapsule, extended release200 mg/1OralREMEDYREPACK INC.2015-09-17Not applicableUs
CarbamazepineCapsule, extended release100 mg/1OralNostrum Laboratories, Inc.2011-05-20Not applicableUs
CarbamazepineTablet, extended release200 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2009-03-31Not applicableUs
CarbamazepineCapsule, extended release100 mg/1OralApotex Corp.2012-03-23Not applicableUs
CarbamazepineTablet, chewable100 mg/1OralTorrent Pharmaceuticals Limited2009-08-26Not applicableUs
CarbamazepineTablet200 mg/1OralTaro Pharmaceuticals U.S.A., Inc.1996-10-03Not applicableUs
CarbamazepineTablet200 mg/1OralA S Medication Solutions Llc1996-10-03Not applicableUs
CarbamazepineTablet200 mg/1OralMajor Pharmaceuticals2010-09-20Not applicableUs
CarbamazepineTablet200 mg/1OralGolden State Medical Supply, Inc.2014-03-07Not applicableUs
CarbamazepineCapsule, extended release200 mg/1OralTeva Pharmaceuticals USA Inc2013-02-11Not applicableUs
CarbamazepineTablet200 mg/1OralAmerican Health Packaging2014-04-15Not applicableUs
CarbamazepineTablet, chewable100 mg/1OralREMEDYREPACK INC.2011-08-172016-10-13Us
CarbamazepineCapsule, extended release100 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2013-06-21Not applicableUs
CarbamazepineTablet200 mg/1OralPreferred Pharmaceuticals, Inc.2014-04-02Not applicableUs
CarbamazepineTablet200 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
CarbamazepineTablet, extended release200 mg/1OralREMEDYREPACK INC.2016-05-04Not applicableUs
CarbamazepineCapsule, extended release300 mg/1OralGolden State Medical Supply, Inc.2011-05-20Not applicableUs
CarbamazepineTablet100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2005-12-07Not applicableUs
CarbamazepineTablet200 mg/1OralMc Kesson Contract Packaging2011-10-07Not applicableUs
CarbamazepineTablet, chewable100 mg/1OralREMEDYREPACK INC.2011-07-132016-11-30Us
CarbamazepineCapsule, extended release200 mg/1OralNostrum Laboratories, Inc.2011-05-20Not applicableUs
CarbamazepineTablet, extended release400 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2009-03-31Not applicableUs
CarbamazepineTablet, chewable100 mg/1OralMylan Institutional Inc.1996-05-15Not applicableUs
CarbamazepineTablet200 mg/1OralCardinal Health1996-10-03Not applicableUs
CarbamazepineTablet200 mg/1OralTeva Pharmaceuticals USA Inc1990-09-30Not applicableUs
CarbamazepineTablet200 mg/1Oralbryant ranch prepack2011-05-03Not applicableUs
CarbamazepineCapsule, extended release200 mg/1OralApotex Corp.2012-03-23Not applicableUs
CarbamazepineTablet200 mg/1OralSTAT Rx USA LLC2009-12-08Not applicableUs
CarbamazepineTablet, chewable100 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2000-10-24Not applicableUs
CarbamazepineTablet200 mg/1OralPhysicians Total Care, Inc.1993-09-23Not applicableUs
CarbamazepineTablet200 mg/1OralA S Medication Solutions2002-09-01Not applicableUs
CarbamazepineSuspension100 mg/5mLOralGolden State Medical Supply, Inc.2004-09-202016-11-11Us
CarbamazepineCapsule, extended release300 mg/1OralTeva Pharmaceuticals USA Inc2013-02-11Not applicableUs
CarbamazepineSuspension200 mg/10mLOralPrecision Dose Inc.2003-09-02Not applicableUs
CarbamazepineTablet200 mg/1OralREMEDYREPACK INC.2010-12-02Not applicableUs
CarbamazepineTablet200 mg/1OralREMEDYREPACK INC.2013-05-08Not applicableUs
CarbamazepineSuspension100 mg/5mLOralAtlantic Biologicals Corps2004-09-20Not applicableUs
CarbamazepineTablet200 mg/1OralUnit Dose Services1996-10-03Not applicableUs
CarbamazepineTablet200 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
CarbamazepineTablet, extended release100 mg/1OralREMEDYREPACK INC.2016-05-06Not applicableUs
CarbamazepineSuspension100 mg/5mLOralMorton Grove Pharmaceuticals, Inc.2002-06-05Not applicableUs
CarbamazepineTablet200 mg/1OralUpsher Smith Laboratories, Inc1996-10-03Not applicableUs
CarbamazepineTablet, chewable100 mg/1OralMc Kesson Contract Packaging2011-09-01Not applicableUs
CarbamazepineTablet, chewable100 mg/1OralTeva Pharmaceuticals USA Inc1995-09-18Not applicableUs
CarbamazepineTablet200 mg/1OralTYA Pharmaceuticals1996-10-03Not applicableUs
CarbamazepineTablet200 mg/1OralAidarex Pharmaceuticals LLC1996-10-03Not applicableUs
CarbamazepineCapsule, extended release300 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2013-06-21Not applicableUs
CarbamazepineTablet200 mg/1OralClinical Solutions Wholesale2009-10-23Not applicableUs
CarbamazepineTablet, chewable100 mg/1OralCardinal Health2000-10-24Not applicableUs
CarbamazepineCapsule, extended release300 mg/1OralApotex Corp.2012-03-23Not applicableUs
CarbamazepineTablet200 mg/1OralRebel Distributors Corp2009-07-01Not applicableUs
CarbamazepineTablet, extended release200 mg/1OralAvera Mc Kennan Hospital2015-05-27Not applicableUs
CarbamazepineSuspension100 mg/5mLOralTaro Pharmaceuticals U.S.A., Inc.2004-09-20Not applicableUs
CarbamazepineTablet, chewable100 mg/1OralPhysicians Total Care, Inc.1995-07-27Not applicableUs
CarbamazepineTablet200 mg/1OralNu Care Pharmaceuticals, Inc.2009-10-23Not applicableUs
CarbamazepineTablet, chewable100 mg/1OralREMEDYREPACK INC.2008-10-27Not applicableUs
CarbamazepineCapsule, extended release100 mg/1OralGolden State Medical Supply, Inc.2011-05-20Not applicableUs
CarbamazepineTablet200 mg/1OralActavis Elizabeth LLC1995-01-03Not applicableUs
CarbamazepineSuspension100 mg/5mLOralPrecision Dose Inc.2007-02-27Not applicableUs
CarbamazepineTablet, chewable200 mg/1OralREMEDYREPACK INC.2013-03-012016-11-29Us
CarbamazepineTablet, chewable100 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
CarbamazepineTablet200 mg/1OralApotex Corp.2002-09-01Not applicableUs
CarbamazepineTablet200 mg/1OralTorrent Pharmaceuticals Limited2009-10-23Not applicableUs
CarbamazepineTablet200 mg/1OralNorthwind Pharmaceuticals, LLC2015-03-03Not applicableUs
CarbamazepineTablet, extended release400 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
CarbamazepineTablet, chewable100 mg/1OralMajor Pharmaceuticals2010-03-22Not applicableUs
CarbamazepineTablet, chewable100 mg/1OralCardinal Health2011-10-28Not applicableUs
CarbamazepineCapsule, extended release100 mg/1OralTeva Pharmaceuticals USA Inc2013-07-15Not applicableUs
CarbamazepineTablet200 mg/1OralContract Pharmacy Services Pa2010-02-24Not applicableUs
CarbamazepineTablet200 mg/1OralPd Rx Pharmaceuticals, Inc.1996-10-03Not applicableUs
CarbamazepineCapsule, extended release200 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2013-06-21Not applicableUs
CarbamazepineTablet, chewable100 mg/1OralClinical Solutions Wholesale2009-08-26Not applicableUs
CarbamazepineTablet200 mg/1OralGolden State Medical Supply, Inc.1996-10-03Not applicableUs
CarbamazepineTablet200 mg/1OralREMEDYREPACK INC.2014-11-26Not applicableUs
CarbamazepineCapsule, extended release300 mg/1OralNostrum Laboratories, Inc.2011-05-20Not applicableUs
CarbamazepineTablet, extended release400 mg/1OralREMEDYREPACK INC.2016-02-18Not applicableUs
CarbamazepineTablet, extended release100 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2009-03-31Not applicableUs
CarbamazepineTablet200 mg/1OralCardinal Health2010-09-20Not applicableUs
EpitolTablet200 mg/1OralTeva Pharmaceuticals USA Inc1990-09-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ActebralSanofi-Aventis
AnlepticSquare
BistonZentiva
CarbamatAstraZeneca
NeurotopGerot
TEGretol ChewtabsNot Available
TEGretol-CRNovartis
TEGretol-XRNovartis
TerilTaro
TimonilDesitin
VersitolMicro Synapse
VersizurMicro Labs
Brand mixturesNot Available
SaltsNot Available
Categories
UNII33CM23913M
CAS number298-46-4
WeightAverage: 236.2686
Monoisotopic: 236.094963016
Chemical FormulaC15H12N2O
InChI KeyFFGPTBGBLSHEPO-UHFFFAOYSA-N
InChI
InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)
IUPAC Name
2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaene-2-carboxamide
SMILES
NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
Pharmacology
IndicationFor the treatment of epilepsy and pain associated with true trigeminal neuralgia.
Structured Indications
PharmacodynamicsCarbamazepine, an anticonvulsant structurally similar to tricyclic antidepressants, is used to treat partial seizures, tonic-clonic seizures, pain of neurologic origin such as trigeminal neuralgia, and psychiatric disorders including manic-depressive illness and aggression due to dementia. The response to carbamazepine is variable and may be due to its variable transport, especially across the blood-brain-barrier. The transporter that may confer drug resistance is RALBP1.
Mechanism of actionCarbamazepine inhibits sustained repetitive firing by blocking use-dependent sodium channels. Pain relief is believed to be associated with blockade of synaptic transmission in the trigeminal nucleus and seizure control with reduction of post-tetanic potentiation of synaptic transmission in the spinal cord. Carbamazepine also possesses anticholinergic, central antidiuretic, antiarrhythmic, muscle relaxant, antidepressant (possibly through blockade of norepinephrine release), sedative, and neuromuscular-blocking properties.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium channel protein type 5 subunit alphaProteinyes
inhibitor
HumanQ14524 details
Related Articles
AbsorptionIn clinical studies, carbamazepine suspension, conventional tablets, and extended-release tablets delivered equivalent amounts of drug to the systemic circulation. However, it has been observed that the suspension is somewhat faster absorbed. Furthermore, the extended-release tablet is slightly slower than the conventional tablet. The bioavailability of the extended-release tablet is 89%, compared to the suspension. Plasma levels of carbamazepine are variable. The time to peak concentration for the different formulations are as follows: Suspension = 1.5 hours; Conventional tablets = 4-5 hours; Extended-release tablets = 3-12 hours.
Volume of distributionNot Available
Protein binding76% bound to plasma proteins.
Metabolism

Hepatic. CYP3A4 is the primary isoform responsible for the formation of carbamazepine-10,11-epoxide. This metabolite is active and shown to be equipotent to carbamazepine as an anticonvulsant. Carbamazepine is more rapidly metabolized to the aforementioned metabolite in younger patients than in adults. It also undergoes glucuronidation via UGT2B7, however this finding has been disputed.

SubstrateEnzymesProduct
Carbamazepine
10,11-EpoxycarbamazepineDetails
Carbamazepine
3-hydroxycarbamazepineDetails
Carbamazepine
Not Available
Carbamazepine 2,3-epoxideDetails
3-hydroxycarbamazepine
2,3-DihydroxycarbamazepineDetails
Carbamazepine 2,3-epoxide
Not Available
2-hydroxycarbamazepineDetails
2-hydroxycarbamazepine
2-hydroxyiminostilbeneDetails
2-hydroxyiminostilbene
Not Available
Carbamazepine iminoquinoneDetails
2-hydroxycarbamazepine
Not Available
2,3-DihydroxycarbamazepineDetails
2,3-Dihydroxycarbamazepine
Not Available
Carbamazepine-O-quinoneDetails
10,11-Epoxycarbamazepine
10,11-DihydroxycarbamazepineDetails
Carbamazepine 2,3-epoxide
Not Available
3-hydroxycarbamazepineDetails
Route of elimination72% of the dose is in the urine while 28% is in the feces. Hydroxylated and conjugated metabolites are largely what was recovered in the urine. 3% of the dose is recovered as unchanged carbamazepine.
Half lifeInitial half-life values range from 25-65 hours, decreasing to 12-17 hours on repeated doses.
ClearanceNot Available
ToxicityMild ingestions cause vomiting, drowsiness, ataxia, slurred speech, nystagmus, dystonic reactions, and hallucinations. Severe intoxications may produce coma, seizures, respiratory depression, and hypotension
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Carbamazepine Metabolism PathwayDrug metabolismSMP00634
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Sodium channel protein type 1 subunit alpha
Gene symbol: SCN1A
UniProt: P35498
rs3812718 Not AvailableIVS5N + 5 G>ACarbamazepine resistant therapy, higher maintenance dose24052718
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Heat shock 70 kDa protein 1-like
Gene symbol: HSPA1L
UniProt: P34931
rs2227956 Not AvailableT alleleHypersensitivity reaction, mild erythematous skin rashes, macropapular eruption, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis16538175
Heat shock 70 kDa protein 1A/1B
Gene symbol: HSPA1A
UniProt: P08107
rs506770 Not AvailableC alleleHypersensitivity reaction, mild erythematous skin rashes, macropapular eruption, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis16538175
Heat shock 70 kDa protein 1A/1B
Gene symbol: HSPA1A
UniProt: P08107
rs1043620 Not AvailableC alleleHypersensitivity reaction, mild erythematous skin rashes, macropapular eruption, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis16538175
HLA class I histocompatibility antigen, B-15 alpha chain
Gene symbol: HLA-B
UniProt: P30464
rs3130690 Not AvailableT alleleStevens-Johnson syndrome (SJS), toxic epidermal necrolysis16538176
HLA class I histocompatibility antigen, A-31 alpha chain
Gene symbol: HLA-A
UniProt: P16189
rs1264511 Not AvailableG alleleMacropapular eruption16538176
Promotilin
Gene symbol: MLN
UniProt: P12872
rs2894342 Not AvailableA alleleHypersensitivity syndrome16538176
Flotillin-1
Gene symbol: FLOT1
UniProt: O75955
rs3909184 HLA-B*1502G > CPatients with the CG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the CC genotype (non-carriers of HLA-b*1502)18637831
Mucin-21
Gene symbol: MUC21
UniProt: Q5SSG8
rs2844682 HLA-B*1502G>APatients with the AG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the AA genotype18637831
Flotillin-1
Gene symbol: FLOT1
UniProt: O75955
rs3909184 HLA-B*1502G > CPatients with the CG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the CC genotype (non-carriers of HLA-b*1502)15057820
Mucin-21
Gene symbol: MUC21
UniProt: Q5SSG8
rs2844682 HLA-B*1502G>APatients with the AG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the AA genotype15057820
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
1,10-PhenanthrolineThe metabolism of 1,10-Phenanthroline can be increased when combined with Carbamazepine.Experimental
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Carbamazepine.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Carbamazepine.Experimental, Illicit
3,4-DichloroisocoumarinThe metabolism of 3,4-Dichloroisocoumarin can be increased when combined with Carbamazepine.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe metabolism of 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE can be increased when combined with Carbamazepine.Experimental
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be decreased when it is combined with Carbamazepine.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be decreased when it is combined with Carbamazepine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Carbamazepine is combined with 7-Nitroindazole.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when Carbamazepine is combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Carbamazepine.Approved
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Carbamazepine.Approved
AceclofenacThe metabolism of Aceclofenac can be increased when combined with Carbamazepine.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Carbamazepine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Carbamazepine.Approved
AcetazolamideThe serum concentration of Carbamazepine can be increased when it is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be increased when combined with Carbamazepine.Approved, Vet Approved
AdenosineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Adenosine.Approved, Investigational
AdinazolamThe metabolism of Adinazolam can be increased when combined with Carbamazepine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Carbamazepine is combined with adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Carbamazepine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Agomelatine.Approved, Investigational
AlbendazoleThe serum concentration of the active metabolites of Albendazole can be reduced when Albendazole is used in combination with Carbamazepine resulting in a loss in efficacy.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be increased when combined with Carbamazepine.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Carbamazepine.Experimental
AlectinibThe serum concentration of Carbamazepine can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Alfaxalone.Vet Approved
AlfentanilThe metabolism of Alfentanil can be increased when combined with Carbamazepine.Approved, Illicit
AlfuzosinThe metabolism of Alfuzosin can be increased when combined with Carbamazepine.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be increased when combined with Carbamazepine.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Carbamazepine.Approved, Investigational
AllopurinolThe serum concentration of Carbamazepine can be increased when it is combined with Allopurinol.Approved
AllylestrenolThe metabolism of Allylestrenol can be increased when combined with Carbamazepine.Approved
AlmotriptanThe metabolism of Almotriptan can be increased when combined with Carbamazepine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be increased when combined with Carbamazepine.Approved
AlosetronThe metabolism of Alosetron can be increased when combined with Carbamazepine.Approved, Withdrawn
Alpha-1-proteinase inhibitorThe metabolism of Alpha-1-proteinase inhibitor can be increased when combined with Carbamazepine.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe metabolism of Alprazolam can be increased when combined with Carbamazepine.Approved, Illicit, Investigational
AmantadineThe serum concentration of Carbamazepine can be increased when it is combined with Amantadine.Approved
AmbrisentanThe metabolism of Ambrisentan can be increased when combined with Carbamazepine.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be increased when combined with Carbamazepine.Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Carbamazepine.Experimental
AmcinonideThe serum concentration of Amcinonide can be decreased when it is combined with Carbamazepine.Approved
AmineptineThe metabolism of Amineptine can be increased when combined with Carbamazepine.Illicit, Withdrawn
Aminohippuric acidThe serum concentration of Carbamazepine can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be increased when combined with Carbamazepine.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Carbamazepine.Approved
AmiodaroneThe metabolism of Amiodarone can be increased when combined with Carbamazepine.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be increased when combined with Carbamazepine.Approved
AmlodipineThe metabolism of Amlodipine can be increased when combined with Carbamazepine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Amodiaquine can be increased when combined with Carbamazepine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Amoxapine.Approved
AmoxicillinThe metabolism of Amoxicillin can be increased when combined with Carbamazepine.Approved, Vet Approved
AmperozideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Amperozide.Experimental
AmprenavirThe metabolism of Amprenavir can be increased when combined with Carbamazepine.Approved
AmsacrineThe serum concentration of Carbamazepine can be increased when it is combined with Amsacrine.Approved
AnagrelideThe metabolism of Anagrelide can be increased when combined with Carbamazepine.Approved
AnecortaveThe serum concentration of Anecortave can be decreased when it is combined with Carbamazepine.Investigational
AntipyrineThe metabolism of Antipyrine can be increased when combined with Carbamazepine.Approved
Antithrombin III humanThe metabolism of Antithrombin III human can be increased when combined with Carbamazepine.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Carbamazepine.Approved
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Carbamazepine.Approved, Investigational
AprepitantThe serum concentration of Carbamazepine can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe metabolism of Aprotinin can be increased when combined with Carbamazepine.Approved, Withdrawn
Arachidonic AcidThe metabolism of Arachidonic Acid can be increased when combined with Carbamazepine.Experimental
ArformoterolThe metabolism of Arformoterol can be increased when combined with Carbamazepine.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be increased when combined with Carbamazepine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Carbamazepine.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Carbamazepine.Approved, Investigational
ArtemetherThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Carbamazepine resulting in a loss in efficacy.Approved
ArticaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Articaine.Approved
ASA404The metabolism of ASA404 can be increased when combined with Carbamazepine.Investigational
AsenapineThe metabolism of Asenapine can be increased when combined with Carbamazepine.Approved
AstemizoleThe metabolism of Astemizole can be increased when combined with Carbamazepine.Approved, Withdrawn
AsunaprevirThe metabolism of Asunaprevir can be increased when combined with Carbamazepine.Approved, Investigational
AtazanavirThe metabolism of Atazanavir can be increased when combined with Carbamazepine.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Carbamazepine.Approved
AtomoxetineThe metabolism of Atomoxetine can be increased when combined with Carbamazepine.Approved
AtorvastatinThe metabolism of Atorvastatin can be increased when combined with Carbamazepine.Approved
AV650The metabolism of AV650 can be increased when combined with Carbamazepine.Approved, Investigational
AvanafilThe metabolism of Avanafil can be increased when combined with Carbamazepine.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Azaperone.Vet Approved
AzelastineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe metabolism of Azelastine can be increased when combined with Carbamazepine.Approved
AzithromycinThe metabolism of Azithromycin can be increased when combined with Carbamazepine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Baclofen.Approved
BanoxantroneThe metabolism of Banoxantrone can be increased when combined with Carbamazepine.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Barbital.Illicit
BatimastatThe metabolism of Batimastat can be increased when combined with Carbamazepine.Experimental
BazedoxifeneThe serum concentration of Bazedoxifene can be decreased when it is combined with Carbamazepine.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Carbamazepine.Investigational
BeclomethasoneThe serum concentration of Beclomethasone can be decreased when it is combined with Carbamazepine.Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Carbamazepine.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Carbamazepine.Approved
BenazeprilThe metabolism of Benazepril can be increased when combined with Carbamazepine.Approved, Investigational
BendamustineThe serum concentration of Bendamustine can be decreased when it is combined with Carbamazepine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Carbamazepine.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Benperidol.Investigational
BenzamidineThe metabolism of Benzamidine can be increased when combined with Carbamazepine.Experimental
BenzatropineThe metabolism of Benzatropine can be increased when combined with Carbamazepine.Approved
BenzocaineThe serum concentration of Carbamazepine can be increased when it is combined with Benzocaine.Approved
BenzphetamineThe metabolism of Benzphetamine can be increased when combined with Carbamazepine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be increased when combined with Carbamazepine.Approved
BepridilThe serum concentration of Carbamazepine can be increased when it is combined with Bepridil.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be increased when combined with Carbamazepine.Investigational
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Carbamazepine.Approved, Vet Approved
BetaxololThe metabolism of Betaxolol can be increased when combined with Carbamazepine.Approved
BexaroteneThe metabolism of Bexarotene can be increased when combined with Carbamazepine.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be increased when combined with Carbamazepine.Approved
Bi201335The metabolism of Bi201335 can be increased when combined with Carbamazepine.Investigational
BicalutamideThe metabolism of Bicalutamide can be increased when combined with Carbamazepine.Approved
BiperidenThe serum concentration of Carbamazepine can be increased when it is combined with Biperiden.Approved
BisoprololThe metabolism of Bisoprolol can be increased when combined with Carbamazepine.Approved
BivalirudinThe metabolism of Bivalirudin can be increased when combined with Carbamazepine.Approved, Investigational
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Carbamazepine.Approved
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Carbamazepine.Approved, Investigational
BosentanThe serum concentration of Carbamazepine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Carbamazepine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Carbamazepine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Carbamazepine.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved
BrinzolamideThe serum concentration of Carbamazepine can be increased when it is combined with Brinzolamide.Approved
BromazepamThe metabolism of Bromazepam can be increased when combined with Carbamazepine.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be increased when combined with Carbamazepine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be increased when combined with Carbamazepine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Brotizolam.Approved, Withdrawn
BudesonideThe metabolism of Budesonide can be increased when combined with Carbamazepine.Approved
BupivacaineThe metabolism of Bupivacaine can be increased when combined with Carbamazepine.Approved, Investigational
BuprenorphineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be increased when combined with Carbamazepine.Approved
BuspironeThe metabolism of Buspirone can be increased when combined with Carbamazepine.Approved, Investigational
BusulfanThe metabolism of Busulfan can be increased when combined with Carbamazepine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Carbamazepine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Butorphanol.Approved, Illicit, Vet Approved
CabazitaxelThe metabolism of Cabazitaxel can be increased when combined with Carbamazepine.Approved
CabergolineThe metabolism of Cabergoline can be increased when combined with Carbamazepine.Approved
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Carbamazepine.Approved
CaffeineThe metabolism of Caffeine can be increased when combined with Carbamazepine.Approved
CalcitriolThe metabolism of Calcitriol can be increased when combined with Carbamazepine.Approved, Nutraceutical
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Carbamazepine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Carbamazepine.Approved
CandesartanThe metabolism of Candesartan can be increased when combined with Carbamazepine.Approved
CandoxatrilThe metabolism of Candoxatril can be increased when combined with Carbamazepine.Experimental
CandoxatrilatThe metabolism of Candoxatrilat can be increased when combined with Carbamazepine.Experimental
CannabidiolThe serum concentration of Cannabidiol can be decreased when it is combined with Carbamazepine.Approved, Investigational
CaptoprilThe metabolism of Captopril can be increased when combined with Carbamazepine.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be increased when combined with Carbamazepine.Approved
CarbomycinThe metabolism of Carbamazepine can be decreased when combined with Carbomycin.Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Carbamazepine.Approved
CariprazineThe metabolism of Cariprazine can be increased when combined with Carbamazepine.Approved
CarisoprodolThe metabolism of Carisoprodol can be increased when combined with Carbamazepine.Approved
CarmustineThe metabolism of Carmustine can be increased when combined with Carbamazepine.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Caroxazone.Withdrawn
CarvedilolThe metabolism of Carvedilol can be increased when combined with Carbamazepine.Approved, Investigational
CaspofunginThe serum concentration of Caspofungin can be decreased when it is combined with Carbamazepine.Approved
CelecoxibThe metabolism of Celecoxib can be increased when combined with Carbamazepine.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be increased when combined with Carbamazepine.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be increased when combined with Carbamazepine.Approved, Vet Approved
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Carbamazepine.Approved
CerivastatinThe metabolism of Cerivastatin can be increased when combined with Carbamazepine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Cetirizine.Approved
CevimelineThe metabolism of Cevimeline can be increased when combined with Carbamazepine.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be increased when combined with Carbamazepine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Chloramphenicol can be increased when combined with Carbamazepine.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be increased when combined with Carbamazepine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Chloroquine can be increased when combined with Carbamazepine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Carbamazepine.Approved, Vet Approved
ChlorotrianiseneThe therapeutic efficacy of Chlorotrianisene can be decreased when used in combination with Carbamazepine.Withdrawn
ChlorphenamineThe metabolism of Chlorphenamine can be increased when combined with Carbamazepine.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be increased when combined with Carbamazepine.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be increased when combined with Carbamazepine.Approved
ChlorprothixeneThe serum concentration of Carbamazepine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Carbamazepine.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be increased when combined with Carbamazepine.Approved
CholecalciferolThe metabolism of Cholecalciferol can be increased when combined with Carbamazepine.Approved, Nutraceutical
CholesterolThe serum concentration of Carbamazepine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Carbamazepine can be decreased when it is combined with Cholic Acid.Approved
ChymostatinThe metabolism of Chymostatin can be increased when combined with Carbamazepine.Experimental
CiclesonideThe metabolism of Ciclesonide can be increased when combined with Carbamazepine.Approved, Investigational
CilastatinThe metabolism of Cilastatin can be increased when combined with Carbamazepine.Approved
CilazaprilThe metabolism of Cilazapril can be increased when combined with Carbamazepine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Carbamazepine.Approved
CimetidineThe serum concentration of Carbamazepine can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Cinacalcet can be increased when combined with Carbamazepine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Carbamazepine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Carbamazepine.Approved
CiprofloxacinThe serum concentration of Carbamazepine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Carbamazepine.Approved, Investigational
CisaprideThe metabolism of Cisapride can be increased when combined with Carbamazepine.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Carbamazepine.Approved
CitalopramThe metabolism of Carbamazepine can be decreased when combined with Citalopram.Approved
ClarithromycinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Carbamazepine.Approved
ClemastineThe metabolism of Carbamazepine can be decreased when combined with Clemastine.Approved
ClenbuterolThe metabolism of Clenbuterol can be increased when combined with Carbamazepine.Approved, Vet Approved
ClevidipineThe metabolism of Clevidipine can be increased when combined with Carbamazepine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Clidinium.Approved
ClindamycinThe metabolism of Clindamycin can be increased when combined with Carbamazepine.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be increased when combined with Carbamazepine.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be decreased when it is combined with Carbamazepine.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be decreased when it is combined with Carbamazepine.Approved
ClocortoloneThe serum concentration of Clocortolone can be decreased when it is combined with Carbamazepine.Approved
ClofazimineThe metabolism of Clofazimine can be increased when combined with Carbamazepine.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be increased when combined with Carbamazepine.Approved
clomethiazoleThe metabolism of clomethiazole can be increased when combined with Carbamazepine.Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Carbamazepine.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Carbamazepine.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be increased when combined with Carbamazepine.Approved, Illicit
ClonidineThe metabolism of Clonidine can be increased when combined with Carbamazepine.Approved
ClopidogrelThe metabolism of Clopidogrel can be increased when combined with Carbamazepine.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be increased when combined with Carbamazepine.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be increased when combined with Carbamazepine.Approved, Illicit
ClotrimazoleThe metabolism of Carbamazepine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineCarbamazepine may increase the myelosuppressive activities of Clozapine.Approved
CobicistatThe serum concentration of Cobicistat can be decreased when it is combined with Carbamazepine.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Carbamazepine.Approved
CocaineThe metabolism of Cocaine can be increased when combined with Carbamazepine.Approved, Illicit
CodeineThe metabolism of Codeine can be increased when combined with Carbamazepine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Carbamazepine.Approved
ColforsinThe serum concentration of Carbamazepine can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Carbamazepine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe therapeutic efficacy of Conjugated Equine Estrogens can be decreased when used in combination with Carbamazepine.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be increased when combined with Carbamazepine.Approved
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Carbamazepine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be increased when combined with Carbamazepine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be increased when combined with Carbamazepine.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Carbamazepine.Approved, Investigational, Vet Approved
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Carbamazepine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Carbamazepine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be increased when combined with Carbamazepine.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Carbamazepine.Approved
DabrafenibThe serum concentration of Carbamazepine can be decreased when it is combined with Dabrafenib.Approved
DacarbazineThe metabolism of Dacarbazine can be increased when combined with Carbamazepine.Approved, Investigational
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Carbamazepine.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Carbamazepine.Approved
DanazolThe metabolism of Carbamazepine can be decreased when combined with Danazol.Approved
DantroleneThe metabolism of Dantrolene can be increased when combined with Carbamazepine.Approved
DapagliflozinThe metabolism of Dapagliflozin can be increased when combined with Carbamazepine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Carbamazepine.Approved
DapoxetineThe metabolism of Carbamazepine can be decreased when combined with Dapoxetine.Investigational
DapsoneThe metabolism of Dapsone can be increased when combined with Carbamazepine.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be increased when combined with Carbamazepine.Approved, Investigational
DarunavirThe serum concentration of Carbamazepine can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Carbamazepine.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be increased when combined with Carbamazepine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Carbamazepine.Approved
DeferasiroxThe serum concentration of Carbamazepine can be decreased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Carbamazepine.Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Carbamazepine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Desflurane.Approved
DesipramineThe metabolism of Desipramine can be increased when combined with Carbamazepine.Approved
DesloratadineThe serum concentration of Carbamazepine can be increased when it is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Desmopressin.Approved
DesogestrelThe therapeutic efficacy of Desogestrel can be decreased when used in combination with Carbamazepine.Approved
DesoximetasoneThe serum concentration of Desoximetasone can be decreased when it is combined with Carbamazepine.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be decreased when it is combined with Carbamazepine.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Carbamazepine.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Carbamazepine can be decreased when combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Carbamazepine.Approved, Investigational, Vet Approved
DexamethasoneThe metabolism of Dexamethasone can be increased when combined with Carbamazepine.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be decreased when it is combined with Carbamazepine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dexbrompheniramine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be increased when combined with Carbamazepine.Approved, Illicit, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be increased when combined with Carbamazepine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe metabolism of Dextropropoxyphene can be increased when combined with Carbamazepine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dezocine.Approved
DiazepamThe metabolism of Diazepam can be increased when combined with Carbamazepine.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be increased when combined with Carbamazepine.Approved, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Carbamazepine.Approved, Vet Approved
DiclofenamideThe serum concentration of Carbamazepine can be increased when it is combined with Diclofenamide.Approved
DicoumarolThe serum concentration of Dicoumarol can be decreased when it is combined with Carbamazepine.Approved
DienestrolThe therapeutic efficacy of Dienestrol can be decreased when used in combination with Carbamazepine.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Carbamazepine.Approved
DiethylstilbestrolThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Carbamazepine.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Difenoxin.Approved, Illicit
DiflorasoneThe serum concentration of Diflorasone can be decreased when it is combined with Carbamazepine.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be decreased when it is combined with Carbamazepine.Approved
DifluprednateThe serum concentration of Difluprednate can be decreased when it is combined with Carbamazepine.Approved
DigitoxinThe metabolism of Digitoxin can be increased when combined with Carbamazepine.Approved
DigoxinThe metabolism of Digoxin can be increased when combined with Carbamazepine.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be increased when combined with Carbamazepine.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be increased when combined with Carbamazepine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Carbamazepine.Illicit
DiltiazemThe serum concentration of Carbamazepine can be increased when it is combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dimenhydrinate.Approved
DinoprostoneThe metabolism of Dinoprostone can be increased when combined with Carbamazepine.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be increased when combined with Carbamazepine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Carbamazepine.Approved
DisopyramideThe metabolism of Disopyramide can be increased when combined with Carbamazepine.Approved
DisulfiramThe metabolism of Disulfiram can be increased when combined with Carbamazepine.Approved
DocetaxelThe metabolism of Docetaxel can be increased when combined with Carbamazepine.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be increased when combined with Carbamazepine.Approved
DolasetronThe metabolism of Dolasetron can be increased when combined with Carbamazepine.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Carbamazepine.Approved
DomperidoneThe metabolism of Domperidone can be increased when combined with Carbamazepine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be increased when combined with Carbamazepine.Approved
DopamineThe metabolism of Dopamine can be increased when combined with Carbamazepine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Doramectin.Vet Approved
DorzolamideThe serum concentration of Carbamazepine can be increased when it is combined with Dorzolamide.Approved
DosulepinThe metabolism of Dosulepin can be increased when combined with Carbamazepine.Approved
DoxazosinThe metabolism of Doxazosin can be increased when combined with Carbamazepine.Approved
DoxepinThe metabolism of Doxepin can be increased when combined with Carbamazepine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Carbamazepine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be increased when combined with Carbamazepine.Approved, Investigational
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Carbamazepine.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Carbamazepine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Carbamazepine.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Vet Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Carbamazepine.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Carbamazepine can be decreased when combined with Duloxetine.Approved
DutasterideThe metabolism of Dutasteride can be increased when combined with Carbamazepine.Approved, Investigational
DyclonineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dyclonine.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Carbamazepine.Approved
EcabetThe metabolism of Ecabet can be increased when combined with Carbamazepine.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Carbamazepine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Carbamazepine.Approved
EfavirenzThe serum concentration of Efavirenz can be decreased when it is combined with Carbamazepine.Approved, Investigational
ElafinThe metabolism of Elafin can be increased when combined with Carbamazepine.Investigational
ElbasvirThe serum concentration of Carbamazepine can be increased when it is combined with Elbasvir.Approved
EletriptanThe metabolism of Eletriptan can be increased when combined with Carbamazepine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Carbamazepine.Approved
EltrombopagThe metabolism of Eltrombopag can be increased when combined with Carbamazepine.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Carbamazepine.Approved
EnalaprilThe metabolism of Enalapril can be increased when combined with Carbamazepine.Approved, Vet Approved
EnalaprilatThe metabolism of Enalaprilat can be increased when combined with Carbamazepine.Approved
EnalkirenThe metabolism of Enalkiren can be increased when combined with Carbamazepine.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Carbamazepine.Approved, Vet Approved
EnfuvirtideThe metabolism of Enfuvirtide can be increased when combined with Carbamazepine.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Carbamazepine.Approved
EpinastineThe metabolism of Epinastine can be increased when combined with Carbamazepine.Approved, Investigational
EplerenoneThe metabolism of Eplerenone can be increased when combined with Carbamazepine.Approved
EpoprostenolThe metabolism of Epoprostenol can be increased when combined with Carbamazepine.Approved
EquileninThe serum concentration of Equilenin can be decreased when it is combined with Carbamazepine.Experimental
EquilinThe serum concentration of Equilin can be decreased when it is combined with Carbamazepine.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be increased when combined with Carbamazepine.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be increased when combined with Carbamazepine.Approved
ErgonovineThe metabolism of Ergonovine can be increased when combined with Carbamazepine.Approved
ErgotamineThe metabolism of Ergotamine can be increased when combined with Carbamazepine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
ErythromycinThe metabolism of Carbamazepine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Carbamazepine can be decreased when combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Carbamazepine.Investigational
EsomeprazoleThe metabolism of Esomeprazole can be increased when combined with Carbamazepine.Approved, Investigational
EstazolamThe metabolism of Estazolam can be increased when combined with Carbamazepine.Approved, Illicit
EstradiolThe therapeutic efficacy of Estradiol can be decreased when used in combination with Carbamazepine.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be increased when combined with Carbamazepine.Approved
EstramustineThe therapeutic efficacy of Estramustine can be decreased when used in combination with Carbamazepine.Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Carbamazepine.Approved, Vet Approved
Estrogens, esterifiedThe therapeutic efficacy of Estrogens, esterified can be decreased when used in combination with Carbamazepine.Approved
EstroneThe metabolism of Estrone can be increased when combined with Carbamazepine.Approved
Estrone sulfateThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Carbamazepine.Approved
EszopicloneThe metabolism of Eszopiclone can be increased when combined with Carbamazepine.Approved
EthanolCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carbamazepine.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Carbamazepine.Approved
EthosuximideThe metabolism of Ethosuximide can be increased when combined with Carbamazepine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethotoin.Approved
EthoxzolamideThe serum concentration of Carbamazepine can be increased when it is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Carbamazepine.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be increased when combined with Carbamazepine.Approved, Illicit
Ethynodiol diacetateThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Carbamazepine.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Etizolam.Approved
EtodolacThe metabolism of Etodolac can be increased when combined with Carbamazepine.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Carbamazepine.Approved
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Carbamazepine.Approved, Investigational
EtoperidoneThe metabolism of Carbamazepine can be decreased when combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Carbamazepine.Approved
EtoricoxibThe metabolism of Etoricoxib can be increased when combined with Carbamazepine.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Carbamazepine.Approved
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Carbamazepine.Approved
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Carbamazepine.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Carbamazepine.Approved
EzogabineThe serum concentration of Ezogabine can be decreased when it is combined with Carbamazepine.Approved
FamciclovirThe metabolism of Famciclovir can be increased when combined with Carbamazepine.Approved
FamotidineThe metabolism of Famotidine can be increased when combined with Carbamazepine.Approved
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Carbamazepine.Approved
FelodipineThe metabolism of Felodipine can be increased when combined with Carbamazepine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenofibrateThe metabolism of Fenofibrate can be increased when combined with Carbamazepine.Approved
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Carbamazepine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe metabolism of Fesoterodine can be increased when combined with Carbamazepine.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Carbamazepine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Carbamazepine.Approved
FinasterideThe metabolism of Finasteride can be increased when combined with Carbamazepine.Approved
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Carbamazepine.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Carbamazepine.Approved
fluasteroneThe serum concentration of fluasterone can be decreased when it is combined with Carbamazepine.Investigational
FluconazoleThe serum concentration of Carbamazepine can be increased when it is combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fludiazepam.Approved, Illicit
FludrocortisoneThe serum concentration of Fludrocortisone can be decreased when it is combined with Carbamazepine.Approved
FluindioneThe serum concentration of Fluindione can be decreased when it is combined with Carbamazepine.Investigational
FlumethasoneThe serum concentration of Flumethasone can be decreased when it is combined with Carbamazepine.Approved, Vet Approved
FlunarizineThe serum concentration of Flunarizine can be decreased when it is combined with Carbamazepine.Approved
FlunisolideThe metabolism of Flunisolide can be increased when combined with Carbamazepine.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be increased when combined with Carbamazepine.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Carbamazepine.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be decreased when it is combined with Carbamazepine.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be decreased when it is combined with Carbamazepine.Approved, Withdrawn
FluorometholoneThe metabolism of Fluorometholone can be increased when combined with Carbamazepine.Approved
FluorouracilThe metabolism of Fluorouracil can be increased when combined with Carbamazepine.Approved
FluoxetineThe metabolism of Carbamazepine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Carbamazepine can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Carbamazepine can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe serum concentration of Fluprednidene can be decreased when it is combined with Carbamazepine.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be decreased when it is combined with Carbamazepine.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be decreased when it is combined with Carbamazepine.Approved
FlurazepamThe metabolism of Flurazepam can be increased when combined with Carbamazepine.Approved, Illicit
FlurbiprofenThe metabolism of Flurbiprofen can be increased when combined with Carbamazepine.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fluspirilene.Approved
FlutamideThe metabolism of Flutamide can be increased when combined with Carbamazepine.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be increased when combined with Carbamazepine.Approved
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be increased when combined with Carbamazepine.Approved
FluvastatinThe metabolism of Fluvastatin can be increased when combined with Carbamazepine.Approved
FluvoxamineThe metabolism of Carbamazepine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe serum concentration of Formestane can be decreased when it is combined with Carbamazepine.Approved, Investigational, Withdrawn
FormoterolThe metabolism of Formoterol can be increased when combined with Carbamazepine.Approved, Investigational
FosamprenavirThe metabolism of Fosamprenavir can be increased when combined with Carbamazepine.Approved
FosaprepitantThe serum concentration of Carbamazepine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe metabolism of Fosinopril can be increased when combined with Carbamazepine.Approved
FosphenytoinThe serum concentration of Carbamazepine can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe metabolism of Frovatriptan can be increased when combined with Carbamazepine.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be increased when combined with Carbamazepine.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Furazolidone.Approved, Vet Approved
Fusidic AcidThe serum concentration of Carbamazepine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Carbamazepine is combined with gabapentin enacarbil.Approved
GabexateThe metabolism of Gabexate can be increased when combined with Carbamazepine.Investigational
GalantamineThe metabolism of Galantamine can be increased when combined with Carbamazepine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GavestinelThe metabolism of Gavestinel can be increased when combined with Carbamazepine.Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
GeldanamycinThe metabolism of Geldanamycin can be increased when combined with Carbamazepine.Experimental
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Carbamazepine.Approved
GemfibrozilThe metabolism of Gemfibrozil can be increased when combined with Carbamazepine.Approved
GenisteinThe metabolism of Genistein can be increased when combined with Carbamazepine.Investigational
GepironeThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Gepirone.Investigational
GestodeneThe therapeutic efficacy of Gestodene can be decreased when used in combination with Carbamazepine.Approved
GliclazideThe metabolism of Gliclazide can be increased when combined with Carbamazepine.Approved
GlimepirideThe metabolism of Glimepiride can be increased when combined with Carbamazepine.Approved
GlipizideThe metabolism of Glipizide can be increased when combined with Carbamazepine.Approved
GlucosamineThe metabolism of Glucosamine can be increased when combined with Carbamazepine.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Glutethimide.Approved, Illicit
GlyburideThe metabolism of Glyburide can be increased when combined with Carbamazepine.Approved
GlycerolThe serum concentration of Carbamazepine can be increased when it is combined with Glycerol.Experimental
GM6001The metabolism of GM6001 can be increased when combined with Carbamazepine.Experimental
Gramicidin DThe serum concentration of Carbamazepine can be increased when it is combined with Gramicidin D.Approved
GranisetronThe metabolism of Granisetron can be increased when combined with Carbamazepine.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Carbamazepine.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be increased when combined with Carbamazepine.Withdrawn
GuanabenzThe metabolism of Guanabenz can be increased when combined with Carbamazepine.Approved
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Carbamazepine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be increased when combined with Carbamazepine.Approved
HaloperidolThe metabolism of Haloperidol can be increased when combined with Carbamazepine.Approved
HalothaneThe metabolism of Halothane can be increased when combined with Carbamazepine.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be decreased when it is combined with Carbamazepine.Investigational
HeroinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Heroin.Approved, Illicit
HesperetinThe metabolism of Hesperetin can be increased when combined with Carbamazepine.Approved
HexestrolThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Carbamazepine.Withdrawn
HexobarbitalThe metabolism of Hexobarbital can be increased when combined with Carbamazepine.Approved
HirulogThe metabolism of Hirulog can be increased when combined with Carbamazepine.Experimental
Histamine PhosphateThe metabolism of Histamine Phosphate can be increased when combined with Carbamazepine.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Hydracarbazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Carbamazepine.Approved, Vet Approved
HydrocodoneCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be increased when combined with Carbamazepine.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Carbamazepine.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Carbamazepine.Approved
HydromorphoneThe metabolism of Hydromorphone can be increased when combined with Carbamazepine.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be increased when combined with Carbamazepine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Carbamazepine.Approved
IbuprofenThe metabolism of Ibuprofen can be increased when combined with Carbamazepine.Approved
IdarubicinThe metabolism of Idarubicin can be increased when combined with Carbamazepine.Approved
IdelalisibThe serum concentration of Carbamazepine can be increased when it is combined with Idelalisib.Approved
idraparinuxThe metabolism of idraparinux can be increased when combined with Carbamazepine.Investigational
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Carbamazepine.Approved
IloperidoneThe metabolism of Iloperidone can be increased when combined with Carbamazepine.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Carbamazepine.Approved
ImidaprilThe metabolism of Imidapril can be increased when combined with Carbamazepine.Investigational
ImipramineThe metabolism of Imipramine can be increased when combined with Carbamazepine.Approved
ImiquimodThe metabolism of Imiquimod can be increased when combined with Carbamazepine.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be increased when combined with Carbamazepine.Approved
IndalpineThe metabolism of Carbamazepine can be decreased when combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Carbamazepine.Approved
IndinavirThe metabolism of Indinavir can be increased when combined with Carbamazepine.Approved
indisulamThe metabolism of indisulam can be increased when combined with Carbamazepine.Investigational
IndomethacinThe metabolism of Indomethacin can be increased when combined with Carbamazepine.Approved, Investigational
Ipratropium bromideThe metabolism of Ipratropium bromide can be increased when combined with Carbamazepine.Approved
IproclozideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Iproniazid.Withdrawn
IrbesartanThe metabolism of Irbesartan can be increased when combined with Carbamazepine.Approved, Investigational
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be reduced when Irinotecan is used in combination with Carbamazepine resulting in a loss in efficacy.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with Carbamazepine resulting in a loss in efficacy.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Isocarboxazid.Approved
IsofluraneThe metabolism of Isoflurane can be increased when combined with Carbamazepine.Approved, Vet Approved
IsoflurophateThe metabolism of Isoflurophate can be increased when combined with Carbamazepine.Approved, Withdrawn
IsoniazidThe metabolism of Carbamazepine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be increased when combined with Carbamazepine.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be increased when combined with Carbamazepine.Approved
IsradipineThe metabolism of Isradipine can be increased when combined with Carbamazepine.Approved
IstaroximeThe serum concentration of Istaroxime can be decreased when it is combined with Carbamazepine.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Carbamazepine.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Carbamazepine.Approved
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Carbamazepine.Approved
IvermectinThe metabolism of Ivermectin can be increased when combined with Carbamazepine.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Carbamazepine.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Carbamazepine.Approved
JosamycinThe metabolism of Carbamazepine can be decreased when combined with Josamycin.Approved
KetamineThe metabolism of Ketamine can be increased when combined with Carbamazepine.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be increased when combined with Carbamazepine.Approved
KetobemidoneThe metabolism of Ketobemidone can be increased when combined with Carbamazepine.Approved
KetoconazoleThe metabolism of Ketoconazole can be increased when combined with Carbamazepine.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be increased when combined with Carbamazepine.Approved, Vet Approved
KitasamycinThe metabolism of Carbamazepine can be decreased when combined with Kitasamycin.Experimental
LacosamideCarbamazepine may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Carbamazepine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Carbamazepine.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be increased when combined with Carbamazepine.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be increased when combined with Carbamazepine.Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Carbamazepine.Approved
LeflunomideThe metabolism of Leflunomide can be increased when combined with Carbamazepine.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Carbamazepine.Approved
LenvatinibThe metabolism of Lenvatinib can be increased when combined with Carbamazepine.Approved
LepirudinThe metabolism of Lepirudin can be increased when combined with Carbamazepine.Approved
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Carbamazepine.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be increased when combined with Carbamazepine.Approved
LetrozoleThe metabolism of Letrozole can be increased when combined with Carbamazepine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Carbamazepine.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be increased when combined with Carbamazepine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Levocabastine.Approved
LevocetirizineThe metabolism of Levocetirizine can be increased when combined with Carbamazepine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Carbamazepine.Approved, Investigational
Levomefolic acidThe serum concentration of Carbamazepine can be decreased when it is combined with Levomefolic acid.Approved
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be increased when combined with Carbamazepine.Approved
LevomilnacipranThe metabolism of Carbamazepine can be decreased when combined with Levomilnacipran.Approved
LevonorgestrelThe therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Carbamazepine.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Levorphanol.Approved
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Carbamazepine.Approved
LicofeloneThe metabolism of Licofelone can be increased when combined with Carbamazepine.Investigational
LidocaineThe metabolism of Lidocaine can be increased when combined with Carbamazepine.Approved, Vet Approved
LinagliptinThe metabolism of Linagliptin can be increased when combined with Carbamazepine.Approved
LiothyronineThe serum concentration of Liothyronine can be decreased when it is combined with Carbamazepine.Approved, Vet Approved
LiotrixThe serum concentration of Liotrix can be decreased when it is combined with Carbamazepine.Approved
LisinoprilThe metabolism of Lisinopril can be increased when combined with Carbamazepine.Approved, Investigational
LisurideThe metabolism of Lisuride can be increased when combined with Carbamazepine.Approved
LithiumThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Lofentanil.Illicit
LomefloxacinThe metabolism of Lomefloxacin can be increased when combined with Carbamazepine.Approved
LomitapideThe metabolism of Lomitapide can be increased when combined with Carbamazepine.Approved
LoperamideThe metabolism of Loperamide can be increased when combined with Carbamazepine.Approved
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Carbamazepine.Approved
LoratadineThe metabolism of Loratadine can be increased when combined with Carbamazepine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Carbamazepine.Approved
LorcaserinThe metabolism of Lorcaserin can be increased when combined with Carbamazepine.Approved
LornoxicamThe metabolism of Lornoxicam can be increased when combined with Carbamazepine.Approved
LosartanThe metabolism of Losartan can be increased when combined with Carbamazepine.Approved
LovastatinThe metabolism of Lovastatin can be increased when combined with Carbamazepine.Approved, Investigational
LoxapineThe serum concentration of the active metabolites of Carbamazepine can be increased when Carbamazepine is used in combination with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Carbamazepine is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Carbamazepine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Carbamazepine can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Carbamazepine.Approved
LumiracoxibThe metabolism of Lumiracoxib can be increased when combined with Carbamazepine.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Carbamazepine.Approved
LynestrenolThe therapeutic efficacy of Lynestrenol can be decreased when used in combination with Carbamazepine.Investigational
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Carbamazepine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Vet Approved
MalathionThe metabolism of Malathion can be increased when combined with Carbamazepine.Approved, Investigational
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Carbamazepine.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be increased when combined with Carbamazepine.Approved
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Carbamazepine.Approved, Investigational
ME-609The serum concentration of ME-609 can be decreased when it is combined with Carbamazepine.Investigational
MebanazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Mebanazine.Withdrawn
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Carbamazepine.Approved, Vet Approved
MeclizineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Medetomidine.Vet Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Carbamazepine.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be decreased when it is combined with Carbamazepine.Approved
Mefenamic acidThe metabolism of Mefenamic acid can be increased when combined with Carbamazepine.Approved
MefloquineThe therapeutic efficacy of Carbamazepine can be decreased when used in combination with Mefloquine.Approved
Megestrol acetateThe serum concentration of Carbamazepine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe metabolism of Melatonin can be increased when combined with Carbamazepine.Approved, Nutraceutical, Vet Approved
MelengestrolThe serum concentration of Melengestrol can be decreased when it is combined with Carbamazepine.Vet Approved
MeloxicamThe metabolism of Meloxicam can be increased when combined with Carbamazepine.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Melperone.Approved
MenadioneThe metabolism of Menadione can be increased when combined with Carbamazepine.Approved, Nutraceutical
MephenytoinThe metabolism of Mephenytoin can be increased when combined with Carbamazepine.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe metabolism of Meprobamate can be increased when combined with Carbamazepine.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Mesoridazine.Approved
MestranolThe therapeutic efficacy of Mestranol can be decreased when used in combination with Carbamazepine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Carbamazepine.Withdrawn
MetaxaloneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Metaxalone.Approved
MethadoneThe metabolism of Methadone can be increased when combined with Carbamazepine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methadyl Acetate.Approved, Illicit
MethallenestrilThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Carbamazepine.Experimental
MethapyrileneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methapyrilene.Withdrawn
MethaqualoneThe metabolism of Methaqualone can be increased when combined with Carbamazepine.Illicit, Withdrawn
MethazolamideThe serum concentration of Carbamazepine can be increased when it is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Carbamazepine.Approved
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Carbamazepine.Approved
MethotrimeprazineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxsalenThe metabolism of Methoxsalen can be increased when combined with Carbamazepine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be increased when combined with Carbamazepine.Approved, Vet Approved
MethsuximideThe metabolism of Methsuximide can be increased when combined with Carbamazepine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carbamazepine.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methylene blue.Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be increased when combined with Carbamazepine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Carbamazepine.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be increased when combined with Carbamazepine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Carbamazepine.Approved
MetoprololThe metabolism of Metoprolol can be increased when combined with Carbamazepine.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be increased when combined with Carbamazepine.Approved
MetyrosineCarbamazepine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Mexiletine can be increased when combined with Carbamazepine.Approved
MianserinThe therapeutic efficacy of Carbamazepine can be decreased when used in combination with Mianserin.Approved
MibefradilThe metabolism of Mibefradil can be increased when combined with Carbamazepine.Withdrawn
MiconazoleThe metabolism of Miconazole can be increased when combined with Carbamazepine.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be increased when combined with Carbamazepine.Approved, Illicit
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Carbamazepine.Approved, Investigational
MilnacipranThe metabolism of Carbamazepine can be decreased when combined with Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be increased when combined with Carbamazepine.Approved
MirtazapineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitomycinThe serum concentration of Carbamazepine can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Carbamazepine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Carbamazepine.Approved, Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Moclobemide.Approved
ModafinilThe metabolism of Modafinil can be increased when combined with Carbamazepine.Approved, Investigational
MoexiprilThe metabolism of Moexipril can be increased when combined with Carbamazepine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Molindone.Approved
MometasoneThe serum concentration of Mometasone can be decreased when it is combined with Carbamazepine.Approved, Vet Approved
MontelukastThe metabolism of Montelukast can be increased when combined with Carbamazepine.Approved
MorphineThe metabolism of Morphine can be increased when combined with Carbamazepine.Approved, Investigational
muraglitazarThe metabolism of muraglitazar can be increased when combined with Carbamazepine.Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be increased when combined with Carbamazepine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe metabolism of N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline can be increased when combined with Carbamazepine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Investigational
NabumetoneThe metabolism of Nabumetone can be increased when combined with Carbamazepine.Approved
NadololThe serum concentration of Nadolol can be decreased when it is combined with Carbamazepine.Approved
NafamostatThe metabolism of Nafamostat can be increased when combined with Carbamazepine.Investigational
NafcillinThe serum concentration of Carbamazepine can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Carbamazepine.Approved
NaloxoneThe metabolism of Naloxone can be increased when combined with Carbamazepine.Approved, Vet Approved
NaltrexoneThe serum concentration of Carbamazepine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe metabolism of Naproxen can be increased when combined with Carbamazepine.Approved, Vet Approved
NaringeninThe serum concentration of Carbamazepine can be increased when it is combined with Naringenin.Experimental
NateglinideThe metabolism of Nateglinide can be increased when combined with Carbamazepine.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be decreased when it is combined with Carbamazepine.Investigational
NCX 4016The metabolism of NCX 4016 can be increased when combined with Carbamazepine.Investigational
NefazodoneThe serum concentration of Carbamazepine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Nelfinavir can be increased when combined with Carbamazepine.Approved
NeostigmineThe serum concentration of Carbamazepine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Netupitant can be decreased when it is combined with Carbamazepine.Approved
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Carbamazepine.Approved
NialamideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Nialamide.Withdrawn
NicardipineThe metabolism of Nicardipine can be increased when combined with Carbamazepine.Approved
NiclosamideThe metabolism of Niclosamide can be increased when combined with Carbamazepine.Approved, Vet Approved
NicotineThe metabolism of Nicotine can be increased when combined with Carbamazepine.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Carbamazepine.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be increased when combined with Carbamazepine.Approved
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Carbamazepine.Approved
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Carbamazepine.Approved
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Carbamazepine.Approved
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Carbamazepine.Approved
NitrazepamThe metabolism of Nitrazepam can be increased when combined with Carbamazepine.Approved
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Carbamazepine.Approved
Nitric OxideThe metabolism of Nitric Oxide can be increased when combined with Carbamazepine.Approved
NitroaspirinThe metabolism of Nitroaspirin can be increased when combined with Carbamazepine.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Carbamazepine.Approved
NorelgestrominThe therapeutic efficacy of Norelgestromin can be decreased when used in combination with Carbamazepine.Approved
NorethisteroneThe metabolism of Norethisterone can be increased when combined with Carbamazepine.Approved
NorgestimateThe therapeutic efficacy of Norgestimate can be decreased when used in combination with Carbamazepine.Approved
NorgestrelThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Carbamazepine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Normethadone.Approved, Illicit
NortriptylineThe metabolism of Nortriptyline can be increased when combined with Carbamazepine.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Octamoxin.Withdrawn
OlanzapineThe metabolism of Olanzapine can be increased when combined with Carbamazepine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Carbamazepine.Approved
OleandomycinThe metabolism of Carbamazepine can be decreased when combined with Oleandomycin.Vet Approved
Oleoyl estroneThe serum concentration of Oleoyl estrone can be decreased when it is combined with Carbamazepine.Investigational
OlodaterolThe metabolism of Olodaterol can be increased when combined with Carbamazepine.Approved
OlopatadineThe metabolism of Olopatadine can be increased when combined with Carbamazepine.Approved
OmapatrilatThe metabolism of Omapatrilat can be increased when combined with Carbamazepine.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Carbamazepine.Approved
OmeprazoleThe metabolism of Omeprazole can be increased when combined with Carbamazepine.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be increased when combined with Carbamazepine.Approved
OpipramolThe metabolism of Opipramol can be increased when combined with Carbamazepine.Investigational
OpiumThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Carbamazepine can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Carbamazepine.Approved
OspemifeneThe metabolism of Ospemifene can be increased when combined with Carbamazepine.Approved
OtamixabanThe metabolism of Otamixaban can be increased when combined with Carbamazepine.Investigational
OxaliplatinThe metabolism of Oxaliplatin can be increased when combined with Carbamazepine.Approved, Investigational
OxaprozinThe metabolism of Oxaprozin can be increased when combined with Carbamazepine.Approved
OxazepamThe metabolism of Oxazepam can be increased when combined with Carbamazepine.Approved
OxcarbazepineThe serum concentration of the active metabolites of Oxcarbazepine can be reduced when Oxcarbazepine is used in combination with Carbamazepine resulting in a loss in efficacy.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Oxetacaine.Investigational
OxiconazoleThe metabolism of Oxiconazole can be increased when combined with Carbamazepine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Oxprenolol.Approved
OxtriphyllineThe metabolism of Oxtriphylline can be increased when combined with Carbamazepine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Oxybuprocaine.Approved
OxybutyninThe metabolism of Oxybutynin can be increased when combined with Carbamazepine.Approved, Investigational
OxycodoneThe metabolism of Oxycodone can be increased when combined with Carbamazepine.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be increased when combined with Carbamazepine.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Carbamazepine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe metabolism of Paclitaxel can be increased when combined with Carbamazepine.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Carbamazepine.Approved
PaliperidoneThe serum concentration of Paliperidone can be decreased when it is combined with Carbamazepine.Approved
Palmitic AcidThe serum concentration of Carbamazepine can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronThe metabolism of Palonosetron can be increased when combined with Carbamazepine.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Carbamazepine.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be increased when combined with Carbamazepine.Approved
ParaldehydeCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParamethadioneThe metabolism of Paramethadione can be increased when combined with Carbamazepine.Approved
ParamethasoneThe metabolism of Paramethasone can be increased when combined with Carbamazepine.Approved
ParecoxibThe metabolism of Parecoxib can be increased when combined with Carbamazepine.Approved
PargylineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pargyline.Approved
ParicalcitolThe metabolism of Paricalcitol can be increased when combined with Carbamazepine.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Carbamazepine.Approved
ParoxetineThe metabolism of Carbamazepine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Carbamazepine.Approved
Peginterferon alfa-2bThe serum concentration of Carbamazepine can be increased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe metabolism of Pentamidine can be increased when combined with Carbamazepine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Carbamazepine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoxifyllineThe metabolism of Pentoxifylline can be increased when combined with Carbamazepine.Approved, Investigational
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Carbamazepine.Approved
PerazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Perazine.Investigational
PergolideThe metabolism of Pergolide can be increased when combined with Carbamazepine.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be increased when combined with Carbamazepine.Approved
PerindoprilThe metabolism of Perindopril can be increased when combined with Carbamazepine.Approved
PermethrinThe metabolism of Permethrin can be increased when combined with Carbamazepine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be increased when combined with Carbamazepine.Approved
PethidineThe metabolism of Pethidine can be increased when combined with Carbamazepine.Approved
PhenacetinThe metabolism of Phenacetin can be increased when combined with Carbamazepine.Withdrawn
PhenelzineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Phenelzine.Approved
PhenindioneThe serum concentration of Phenindione can be decreased when it is combined with Carbamazepine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Carbamazepine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be increased when combined with Carbamazepine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Phenoxypropazine.Withdrawn
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Carbamazepine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be increased when combined with Carbamazepine.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Carbamazepine.Approved, Vet Approved
PhosphoramidonThe metabolism of Phosphoramidon can be increased when combined with Carbamazepine.Experimental
PilocarpineThe metabolism of Pilocarpine can be increased when combined with Carbamazepine.Approved
PimecrolimusThe metabolism of Pimecrolimus can be increased when combined with Carbamazepine.Approved, Investigational
PimozideThe metabolism of Pimozide can be increased when combined with Carbamazepine.Approved
PinacidilThe metabolism of Pinacidil can be increased when combined with Carbamazepine.Withdrawn
PioglitazoneThe metabolism of Pioglitazone can be increased when combined with Carbamazepine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pipamperone.Approved
PipotiazineThe metabolism of Pipotiazine can be increased when combined with Carbamazepine.Approved
PirfenidoneThe serum concentration of Pirfenidone can be decreased when it is combined with Carbamazepine.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pirlindole.Approved
PiroxicamThe metabolism of Piroxicam can be increased when combined with Carbamazepine.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be increased when combined with Carbamazepine.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Carbamazepine can be decreased when it is combined with Platelet Activating Factor.Experimental
PodofiloxThe metabolism of Podofilox can be increased when combined with Carbamazepine.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Carbamazepine.Approved
PomalidomideThe metabolism of Pomalidomide can be increased when combined with Carbamazepine.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Carbamazepine.Approved
PosaconazoleThe metabolism of Posaconazole can be increased when combined with Carbamazepine.Approved, Investigational, Vet Approved
PramipexoleCarbamazepine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pramocaine.Approved
PrasteroneThe metabolism of Prasterone can be increased when combined with Carbamazepine.Approved, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be increased when combined with Carbamazepine.Approved
PravastatinThe metabolism of Pravastatin can be increased when combined with Carbamazepine.Approved
PrazepamThe metabolism of Prazepam can be increased when combined with Carbamazepine.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Carbamazepine.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Carbamazepine.Approved
PrednicarbateThe serum concentration of Prednicarbate can be decreased when it is combined with Carbamazepine.Approved
PrednisoloneThe metabolism of Prednisolone can be increased when combined with Carbamazepine.Approved, Vet Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Carbamazepine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Carbamazepine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Carbamazepine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pregnanolone.Investigational
PregnenoloneThe serum concentration of Pregnenolone can be decreased when it is combined with Carbamazepine.Experimental
PrilocaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Prilocaine.Approved
PrimaquineThe metabolism of Primaquine can be increased when combined with Carbamazepine.Approved
PrimidoneThe metabolism of Carbamazepine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe metabolism of Prinomastat can be increased when combined with Carbamazepine.Investigational
ProbenecidThe serum concentration of Carbamazepine can be increased when it is combined with Probenecid.Approved
ProcaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe metabolism of Prochlorperazine can be increased when combined with Carbamazepine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be increased when combined with Carbamazepine.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be increased when combined with Carbamazepine.Approved
PromazineThe metabolism of Promazine can be increased when combined with Carbamazepine.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be increased when combined with Carbamazepine.Approved
PropacetamolThe metabolism of Propacetamol can be increased when combined with Carbamazepine.Approved
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Carbamazepine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Proparacaine.Approved, Vet Approved
PropofolThe metabolism of Propofol can be increased when combined with Carbamazepine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Propoxycaine.Approved
PropranololThe metabolism of Propranolol can be increased when combined with Carbamazepine.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be increased when combined with Carbamazepine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Carbamazepine.Approved
PSD502The risk or severity of adverse effects can be increased when Carbamazepine is combined with PSD502.Investigational
PyrazinamideThe metabolism of Pyrazinamide can be increased when combined with Carbamazepine.Approved
QuazepamThe metabolism of Quazepam can be increased when combined with Carbamazepine.Approved, Illicit
QuercetinThe serum concentration of Carbamazepine can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of the active metabolites of Carbamazepine can be increased when Carbamazepine is used in combination with Quetiapine.Approved
QuinacrineThe metabolism of Quinacrine can be increased when combined with Carbamazepine.Approved
QuinaprilThe metabolism of Quinapril can be increased when combined with Carbamazepine.Approved, Investigational
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Carbamazepine.Approved
QuinidineThe metabolism of Quinidine can be increased when combined with Carbamazepine.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Carbamazepine.Approved
RabeprazoleThe metabolism of Rabeprazole can be increased when combined with Carbamazepine.Approved, Investigational
RacecadotrilThe metabolism of Racecadotril can be increased when combined with Carbamazepine.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Raclopride.Investigational
RaloxifeneThe metabolism of Raloxifene can be increased when combined with Carbamazepine.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be increased when combined with Carbamazepine.Approved, Investigational
RamiprilThe metabolism of Ramipril can be increased when combined with Carbamazepine.Approved
RanitidineThe metabolism of Ranitidine can be increased when combined with Carbamazepine.Approved
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Carbamazepine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Rasagiline.Approved
ReboxetineThe metabolism of Reboxetine can be increased when combined with Carbamazepine.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Carbamazepine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Remifentanil.Approved
RemikirenThe metabolism of Remikiren can be increased when combined with Carbamazepine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Carbamazepine.Approved, Withdrawn
RepaglinideThe metabolism of Repaglinide can be increased when combined with Carbamazepine.Approved, Investigational
ReserpineThe serum concentration of Carbamazepine can be decreased when it is combined with Reserpine.Approved
ResveratrolThe metabolism of Resveratrol can be increased when combined with Carbamazepine.Experimental, Investigational
RetapamulinThe metabolism of Retapamulin can be increased when combined with Carbamazepine.Approved
RifabutinThe metabolism of Rifabutin can be increased when combined with Carbamazepine.Approved
RifampicinThe metabolism of Rifampicin can be increased when combined with Carbamazepine.Approved
RifapentineThe metabolism of Carbamazepine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Carbamazepine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Carbamazepine.Approved
RiluzoleThe metabolism of Riluzole can be increased when combined with Carbamazepine.Approved, Investigational
RimexoloneThe serum concentration of Rimexolone can be decreased when it is combined with Carbamazepine.Approved
RimonabantThe metabolism of Rimonabant can be increased when combined with Carbamazepine.Approved, Investigational
RiociguatThe metabolism of Riociguat can be increased when combined with Carbamazepine.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Carbamazepine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ritanserin.Investigational
RitonavirThe metabolism of Ritonavir can be increased when combined with Carbamazepine.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Carbamazepine.Approved
RizatriptanThe metabolism of Rizatriptan can be increased when combined with Carbamazepine.Approved
RofecoxibThe metabolism of Rofecoxib can be increased when combined with Carbamazepine.Investigational, Withdrawn
RoflumilastThe serum concentration of Roflumilast can be decreased when it is combined with Carbamazepine.Approved
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Carbamazepine.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Carbamazepine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Romifidine.Vet Approved
RopiniroleCarbamazepine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be increased when combined with Carbamazepine.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be increased when combined with Carbamazepine.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be increased when combined with Carbamazepine.Approved
RotigotineCarbamazepine may increase the sedative activities of Rotigotine.Approved
RoxithromycinThe metabolism of Roxithromycin can be increased when combined with Carbamazepine.Approved, Withdrawn
RufinamideThe serum concentration of Carbamazepine can be decreased when it is combined with Rufinamide.Approved
RuxolitinibThe metabolism of Ruxolitinib can be increased when combined with Carbamazepine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Carbamazepine is combined with S-Ethylisothiourea.Experimental
SafrazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Safrazine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Carbamazepine is combined with Sage 547.Investigational
Salicylic acidThe metabolism of Salicylic acid can be increased when combined with Carbamazepine.Approved, Vet Approved
SalmeterolThe metabolism of Salmeterol can be increased when combined with Carbamazepine.Approved
SaquinavirThe metabolism of Saquinavir can be increased when combined with Carbamazepine.Approved, Investigational
SaxagliptinThe metabolism of Saxagliptin can be increased when combined with Carbamazepine.Approved
ScopolamineThe serum concentration of Carbamazepine can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Carbamazepine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be increased when combined with Carbamazepine.Approved
SeratrodastThe metabolism of Seratrodast can be increased when combined with Carbamazepine.Approved, Investigational
SertindoleThe metabolism of Sertindole can be increased when combined with Carbamazepine.Approved, Withdrawn
SertralineThe metabolism of Carbamazepine can be decreased when combined with Sertraline.Approved
SevofluraneThe metabolism of Sevoflurane can be increased when combined with Carbamazepine.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be increased when combined with Carbamazepine.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Sildenafil can be increased when combined with Carbamazepine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Carbamazepine.Approved
SiltuximabThe serum concentration of Carbamazepine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Carbamazepine.Approved
SimvastatinThe metabolism of Simvastatin can be increased when combined with Carbamazepine.Approved
SirolimusThe metabolism of Sirolimus can be increased when combined with Carbamazepine.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be increased when combined with Carbamazepine.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be increased when combined with Carbamazepine.Approved, Investigational, Withdrawn
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Carbamazepine.Approved
SolifenacinThe metabolism of Solifenacin can be increased when combined with Carbamazepine.Approved
SolithromycinThe metabolism of Carbamazepine can be decreased when combined with Solithromycin.Investigational
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Carbamazepine.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Carbamazepine.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Carbamazepine.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Carbamazepine.Experimental
SpiramycinThe metabolism of Spiramycin can be increased when combined with Carbamazepine.Approved
SpiraprilThe metabolism of Spirapril can be increased when combined with Carbamazepine.Approved
SpironolactoneThe serum concentration of Carbamazepine can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Carbamazepine can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Carbamazepine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Carbamazepine can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Carbamazepine can be decreased when it is combined with Streptozocin.Approved
SufentanilThe metabolism of Sufentanil can be increased when combined with Carbamazepine.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be increased when combined with Carbamazepine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be increased when combined with Carbamazepine.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be increased when combined with Carbamazepine.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be increased when combined with Carbamazepine.Approved
SulfisoxazoleThe metabolism of Sulfisoxazole can be increased when combined with Carbamazepine.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Carbamazepine.Approved
SumatriptanThe serum concentration of Carbamazepine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
SuprofenThe metabolism of Suprofen can be increased when combined with Carbamazepine.Approved, Withdrawn
SuvorexantThe serum concentration of Suvorexant can be decreased when it is combined with Carbamazepine.Approved
Synthetic Conjugated Estrogens, AThe therapeutic efficacy of Synthetic Conjugated Estrogens, A can be decreased when used in combination with Carbamazepine.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Carbamazepine.Approved
TacrineThe metabolism of Tacrine can be increased when combined with Carbamazepine.Withdrawn
TacrolimusThe metabolism of Tacrolimus can be increased when combined with Carbamazepine.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Carbamazepine.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be increased when combined with Carbamazepine.Approved
TamsulosinThe metabolism of Tamsulosin can be increased when combined with Carbamazepine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved
TasimelteonThe serum concentration of Tasimelteon can be decreased when it is combined with Carbamazepine.Approved
TasosartanThe metabolism of Tasosartan can be increased when combined with Carbamazepine.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be increased when combined with Carbamazepine.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Carbamazepine.Experimental
TazaroteneThe metabolism of Tazarotene can be increased when combined with Carbamazepine.Approved, Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Carbamazepine.Approved
TelaprevirThe serum concentration of Carbamazepine can be increased when it is combined with Telaprevir.Approved
TelithromycinThe metabolism of Carbamazepine can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Carbamazepine can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe metabolism of Temafloxacin can be increased when combined with Carbamazepine.Withdrawn
TemazepamThe metabolism of Temazepam can be increased when combined with Carbamazepine.Approved
TemocaprilThe metabolism of Temocapril can be increased when combined with Carbamazepine.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Carbamazepine.Approved
TeniposideThe metabolism of Teniposide can be increased when combined with Carbamazepine.Approved
TenofovirThe metabolism of Carbamazepine can be decreased when combined with Tenofovir.Approved, Investigational
TenoxicamThe metabolism of Tenoxicam can be increased when combined with Carbamazepine.Approved
TerazosinThe serum concentration of Carbamazepine can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be increased when combined with Carbamazepine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be increased when combined with Carbamazepine.Withdrawn
TeriflunomideThe serum concentration of Carbamazepine can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be increased when combined with Carbamazepine.Investigational
TestosteroneThe metabolism of Testosterone can be increased when combined with Carbamazepine.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tetracaine.Approved, Vet Approved
TetracyclineThe metabolism of Tetracycline can be increased when combined with Carbamazepine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tetrodotoxin.Investigational
ThalidomideCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe metabolism of Theobromine can be increased when combined with Carbamazepine.Approved
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Carbamazepine.Approved
ThiabendazoleThe metabolism of Thiabendazole can be increased when combined with Carbamazepine.Approved, Vet Approved
ThiamylalThe metabolism of Thiamylal can be increased when combined with Carbamazepine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Thioridazine can be increased when combined with Carbamazepine.Approved
ThiorphanThe metabolism of Thiorphan can be increased when combined with Carbamazepine.Experimental
ThiotepaThe metabolism of Thiotepa can be increased when combined with Carbamazepine.Approved
ThiothixeneThe metabolism of Thiothixene can be increased when combined with Carbamazepine.Approved
Thyroid, porcineThe serum concentration of Thyroid, porcine can be decreased when it is combined with Carbamazepine.Approved
TiagabineThe metabolism of Tiagabine can be increased when combined with Carbamazepine.Approved
TianeptineThe metabolism of Tianeptine can be increased when combined with Carbamazepine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tiapride.Investigational
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Carbamazepine resulting in a loss in efficacy.Approved
TiclopidineThe metabolism of Ticlopidine can be increased when combined with Carbamazepine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tiletamine.Vet Approved
TimololThe metabolism of Timolol can be increased when combined with Carbamazepine.Approved
TinidazoleThe metabolism of Tinidazole can be increased when combined with Carbamazepine.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be increased when combined with Carbamazepine.Approved
TipranavirThe metabolism of Tipranavir can be increased when combined with Carbamazepine.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be decreased when it is combined with Carbamazepine.Approved
TizanidineThe metabolism of Tizanidine can be increased when combined with Carbamazepine.Approved
TocilizumabThe serum concentration of Carbamazepine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
TolbutamideThe metabolism of Tolbutamide can be increased when combined with Carbamazepine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Toloxatone.Approved
TolterodineThe metabolism of Tolterodine can be increased when combined with Carbamazepine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Carbamazepine.Approved
TopiramateThe serum concentration of Topiramate can be decreased when it is combined with Carbamazepine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Carbamazepine.Approved, Investigational
TorasemideThe metabolism of Torasemide can be increased when combined with Carbamazepine.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Carbamazepine.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Carbamazepine.Approved, Investigational
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Investigational
TrandolaprilThe metabolism of Trandolapril can be increased when combined with Carbamazepine.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tranylcypromine.Approved
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be increased when combined with Carbamazepine.Approved
TrazodoneThe metabolism of Trazodone can be increased when combined with Carbamazepine.Approved, Investigational
TreprostinilThe serum concentration of Treprostinil can be decreased when it is combined with Carbamazepine.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be increased when combined with Carbamazepine.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be increased when combined with Carbamazepine.Approved, Vet Approved
TriamtereneThe metabolism of Triamterene can be increased when combined with Carbamazepine.Approved
TriazolamThe metabolism of Triazolam can be increased when combined with Carbamazepine.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Carbamazepine.Approved, Vet Approved
TrifluoperazineThe metabolism of Trifluoperazine can be increased when combined with Carbamazepine.Approved
TriflupromazineThe serum concentration of Carbamazepine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be increased when combined with Carbamazepine.Approved
TrimethoprimThe metabolism of Trimethoprim can be increased when combined with Carbamazepine.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be increased when combined with Carbamazepine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Triprolidine.Approved
TroglitazoneThe metabolism of Troglitazone can be increased when combined with Carbamazepine.Withdrawn
TroleandomycinThe metabolism of Carbamazepine can be decreased when combined with Troleandomycin.Approved
TylosinThe metabolism of Carbamazepine can be decreased when combined with Tylosin.Vet Approved
UbenimexThe metabolism of Ubenimex can be increased when combined with Carbamazepine.Experimental
Uc1010The risk or severity of adverse effects can be increased when Carbamazepine is combined with Uc1010.Investigational
UdenafilThe metabolism of Udenafil can be increased when combined with Carbamazepine.Approved, Investigational
UlinastatinThe metabolism of Ulinastatin can be increased when combined with Carbamazepine.Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Carbamazepine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Carbamazepine.Approved
ValdecoxibThe metabolism of Valdecoxib can be increased when combined with Carbamazepine.Investigational, Withdrawn
Valproic AcidThe serum concentration of the active metabolites of Carbamazepine can be increased when Carbamazepine is used in combination with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Valsartan can be increased when combined with Carbamazepine.Approved, Investigational
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Carbamazepine.Approved
VanoxerineThe metabolism of Vanoxerine can be increased when combined with Carbamazepine.Investigational
VardenafilThe metabolism of Vardenafil can be increased when combined with Carbamazepine.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Carbamazepine.Approved
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Carbamazepine.Approved
VenetoclaxThe metabolism of Venetoclax can be increased when combined with Carbamazepine.Approved
VenlafaxineThe metabolism of Carbamazepine can be decreased when combined with Venlafaxine.Approved
VerapamilThe serum concentration of Carbamazepine can be increased when it is combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be increased when combined with Carbamazepine.Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Vigabatrin.Approved
VilanterolThe metabolism of Vilanterol can be increased when combined with Carbamazepine.Approved
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Carbamazepine.Approved
VildagliptinThe metabolism of Vildagliptin can be increased when combined with Carbamazepine.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be increased when combined with Carbamazepine.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Carbamazepine.Approved, Investigational
VincristineThe metabolism of Vincristine can be increased when combined with Carbamazepine.Approved, Investigational
VindesineThe metabolism of Vindesine can be increased when combined with Carbamazepine.Approved
VinorelbineThe metabolism of Vinorelbine can be increased when combined with Carbamazepine.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be increased when combined with Carbamazepine.Approved
VorapaxarThe serum concentration of Vorapaxar can be decreased when it is combined with Carbamazepine.Approved
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Carbamazepine.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Carbamazepine.Approved
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Carbamazepine.Approved
XimelagatranThe metabolism of Ximelagatran can be increased when combined with Carbamazepine.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Xylazine.Vet Approved
Ym150The metabolism of Ym150 can be increased when combined with Carbamazepine.Investigational
YohimbineThe metabolism of Yohimbine can be increased when combined with Carbamazepine.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be increased when combined with Carbamazepine.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be increased when combined with Carbamazepine.Approved
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Carbamazepine.Approved, Illicit, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be increased when combined with Carbamazepine.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ziconotide.Approved
ZidovudineThe metabolism of Zidovudine can be increased when combined with Carbamazepine.Approved
ZileutonThe metabolism of Zileuton can be increased when combined with Carbamazepine.Approved, Investigational, Withdrawn
ZimelidineThe metabolism of Carbamazepine can be decreased when combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Carbamazepine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Zolazepam.Vet Approved
ZolmitriptanThe metabolism of Zolmitriptan can be increased when combined with Carbamazepine.Approved, Investigational
ZolpidemZolpidem may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved
ZomepiracThe metabolism of Zomepirac can be increased when combined with Carbamazepine.Withdrawn
ZonisamideThe metabolism of Zonisamide can be increased when combined with Carbamazepine.Approved, Investigational
ZopicloneThe metabolism of Zopiclone can be increased when combined with Carbamazepine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Zotepine.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be decreased when it is combined with Carbamazepine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid taking grapefruit or grapefruit juice throughout treatment.
  • Grapefruit can significantly increase serum levels of this product.
  • Take with food, increases availability and reduces irritation.
References
Synthesis Reference

Ketan Dhansukhlal Vyas, Wajid Sajjad Jafri, Ashok Krishna Kulkarni, “Process for preparing carbamazepine from iminostilbene.” U.S. Patent US6245908, issued February, 1998.

US6245908
General References
  1. Staines AG, Coughtrie MW, Burchell B: N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. J Pharmacol Exp Ther. 2004 Dec;311(3):1131-7. Epub 2004 Aug 3. [PubMed:15292462 ]
  2. Sisodiya SM, Goldstein DB: Drug resistance in epilepsy: more twists in the tale. Epilepsia. 2007 Dec;48(12):2369-70. [PubMed:18088268 ]
External Links
ATC CodesN03AF01
AHFS Codes
  • 28:12.92
PDB EntriesNot Available
FDA labelDownload (55.9 KB)
MSDSDownload (71.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9962
Blood Brain Barrier+0.9958
Caco-2 permeable+0.6538
P-glycoprotein substrateNon-substrate0.6466
P-glycoprotein inhibitor INon-inhibitor0.8748
P-glycoprotein inhibitor IINon-inhibitor0.8381
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.7466
CYP450 2D6 substrateSubstrate0.884
CYP450 3A4 substrateNon-substrate0.6204
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8222
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7358
Ames testNon AMES toxic0.5554
CarcinogenicityNon-carcinogens0.8848
BiodegradationNot ready biodegradable0.978
Rat acute toxicity2.1131 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9653
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Shire development inc
  • Validus pharmaceuticals inc
  • Taro pharmaceutical industries ltd
  • Wockhardt eu operations (swiss) ag
  • Novartis pharmaceuticals corp
  • Taro pharmaceuticals usa inc
  • Cadista pharmaceuticals inc
  • Torrent pharmaceuticals ltd
  • Teva pharmaceuticals usa inc
  • Actavis elizabeth llc
  • Apotex inc etobicoke site
  • Inwood laboratories inc sub forest laboratories inc
  • Pliva inc
  • Usl pharma inc
  • Warner chilcott div warner lambert co
Packagers
Dosage forms
FormRouteStrength
TabletOral200 mg
Capsule, extended releaseOral100 mg/1
Capsule, extended releaseOral200 mg/1
Capsule, extended releaseOral300 mg/1
SuspensionOral200 mg/10mL
TabletOral100 mg/1
Tablet, chewableOral100 mg/1
Tablet, chewableOral200 mg/1
Injection, powder, for solutionIntravenous10 mg/mL
Tablet, chewableOral100 mg
Tablet, chewableOral200 mg
Tablet, extended releaseOral200 mg
Tablet, extended releaseOral400 mg
SuspensionOral100 mg/5mL
TabletOral200 mg/1
SuspensionOral100 mg
TabletOral100 mg
Tablet, extended releaseOral100 mg/1
Tablet, extended releaseOral200 mg/1
Tablet, extended releaseOral400 mg/1
Prices
Unit descriptionCostUnit
Equetro 300 mg capsule2.65USD capsule
TEGretol XR 400 mg 12 Hour tablet2.42USD tablet
Carbamazepine powder2.26USD g
Tegretol xr 400 mg tablet2.19USD tablet
Carbatrol 100 mg 12 Hour Capsule2.18USD capsule
Equetro 200 mg capsule2.15USD capsule
CarBAMazepine 400 mg 12 Hour tablet2.05USD tablet
Carbatrol 300 mg 12 Hour Capsule1.95USD capsule
Carbatrol 200 mg 12 Hour Capsule1.92USD capsule
Carbatrol er 100 mg capsule1.84USD capsule
Carbatrol er 200 mg capsule1.84USD capsule
Carbatrol er 300 mg capsule1.84USD capsule
Equetro 100 mg capsule1.74USD capsule
TEGretol XR 200 mg 12 Hour tablet1.45USD tablet
Tegretol xr 200 mg tablet1.1USD tablet
CarBAMazepine 200 mg 12 Hour tablet1.03USD tablet
TEGretol XR 100 mg 12 Hour tablet0.97USD tablet
Tegretol Cr 400 mg Sustained-Release Tablet0.84USD tablet
Tegretol 200 mg tablet0.75USD tablet
Tegretol xr 100 mg tablet0.55USD tablet
Tegretol Cr 200 mg Sustained-Release Tablet0.42USD tablet
Mylan-Carbamazepine Cr 400 mg Sustained-Release Tablet0.4USD tablet
Pms-Carbamazepine-Cr 400 mg Sustained-Release Tablet0.4USD tablet
Sandoz Carbamazepine Cr 400 mg Sustained-Release Tablet0.4USD tablet
Tegretol 200 mg Chewable Tablet0.34USD tablet
Carbamazepine 200 mg tablet0.31USD tablet
Epitol 200 mg tablet0.3USD tablet
CarBAMazepine 100 mg Chew Tabs0.25USD tab
Mylan-Carbamazepine Cr 200 mg Sustained-Release Tablet0.2USD tablet
Pms-Carbamazepine-Cr 200 mg Sustained-Release Tablet0.2USD tablet
Sandoz Carbamazepine Cr 200 mg Sustained-Release Tablet0.2USD tablet
Tegretol 100 mg Chewable Tablet0.17USD tablet
CarBAMazepine 100 mg/5ml Suspension0.16USD ml
Pms-Carbamazepine 200 mg Chewable Tablet0.16USD tablet
Sandoz Carbamazepine 200 mg Chewable Tablet0.16USD tablet
Taro-Carbamazepine 200 mg Chewable Tablet0.16USD tablet
Apo-Carbamazepine 200 mg Tablet0.08USD tablet
Novo-Carbamaz 200 mg Tablet0.08USD tablet
Nu-Carbamazepine 200 mg Tablet0.08USD tablet
Pms-Carbamazepine 100 mg Chewable Tablet0.08USD tablet
Sandoz Carbamazepine 100 mg Chewable Tablet0.08USD tablet
Taro-Carbamazepine 100 mg Chewable Tablet0.08USD tablet
Tegretol 20 mg/ml Suspension0.08USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5284662 No1994-02-082011-02-08Us
US5912013 No1996-06-152016-06-15Us
US6977253 No2004-05-192024-05-19Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point204-206Schindier, W.; U.S. Patent 2,948,718; August 9, 1960; assigned to Geigy Chemical Corporation.
water solubility17.7 mg/LNot Available
logP2.45DAL POZZO,A ET AL. (1989)
Predicted Properties
PropertyValueSource
Water Solubility0.152 mg/mLALOGPS
logP2.1ALOGPS
logP2.77ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)15.96ChemAxon
pKa (Strongest Basic)-3.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.33 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity71.89 m3·mol-1ChemAxon
Polarizability25 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.72 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0006-1910000000-4b2dc85e8da73b101ed2View in MoNA
1D NMR1H NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzazepines
Sub ClassDibenzazepines
Direct ParentDibenzazepines
Alternative Parents
Substituents
  • Dibenzazepine
  • Azepine
  • Benzenoid
  • Urea
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function:
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is respon...
Gene Name:
SCN5A
Uniprot ID:
Q14524
Molecular Weight:
226937.475 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Yang YC, Huang CS, Kuo CC: Lidocaine, carbamazepine, and imipramine have partially overlapping binding sites and additive inhibitory effect on neuronal Na+ channels. Anesthesiology. 2010 Jul;113(1):160-74. doi: 10.1097/ALN.0b013e3181dc1dd6. [PubMed:20526191 ]
  4. Yang YC, Kuo CC: Inhibition of Na(+) current by imipramine and related compounds: different binding kinetics as an inactivation stabilizer and as an open channel blocker. Mol Pharmacol. 2002 Nov;62(5):1228-37. [PubMed:12391287 ]
  5. Lipkind GM, Fozzard HA: Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore. Mol Pharmacol. 2010 Oct;78(4):631-8. doi: 10.1124/mol.110.064683. Epub 2010 Jul 19. [PubMed:20643904 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577 ]
  2. Levy RH: Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia. 1995;36 Suppl 5:S8-13. [PubMed:8806399 ]
  3. Cazali N, Tran A, Treluyer JM, Rey E, d'Athis P, Vincent J, Pons G: Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol. 2003 Nov;56(5):526-36. [PubMed:14651727 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Cazali N, Tran A, Treluyer JM, Rey E, d'Athis P, Vincent J, Pons G: Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol. 2003 Nov;56(5):526-36. [PubMed:14651727 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Kim KA, Oh SO, Park PW, Park JY: Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. Eur J Clin Pharmacol. 2005 Jun;61(4):275-80. Epub 2005 May 25. [PubMed:15915352 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. [PubMed:11297522 ]
  2. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK: Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol. 2001 Apr;51(4):345-9. [PubMed:11318771 ]
  3. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
  4. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309 ]
  5. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transmembrane transporter activity
Specific Function:
Can activate specifically hydrolysis of GTP bound to RAC1 and CDC42, but not RALA. Mediates ATP-dependent transport of S-(2,4-dinitrophenyl)-glutathione (DNP-SG) and doxorubicin (DOX) and is the major ATP-dependent transporter of glutathione conjugates of electrophiles (GS-E) and DOX in erythrocytes. Can catalyze transport of glutathione conjugates and xenobiotics, and may contribute to the mul...
Gene Name:
RALBP1
Uniprot ID:
Q15311
Molecular Weight:
76062.86 Da
References
  1. Awasthi S, Hallene KL, Fazio V, Singhal SS, Cucullo L, Awasthi YC, Dini G, Janigro D: RLIP76, a non-ABC transporter, and drug resistance in epilepsy. BMC Neurosci. 2005 Sep 27;6:61. [PubMed:16188027 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Ufer M, Mosyagin I, Muhle H, Jacobsen T, Haenisch S, Hasler R, Faltraco F, Remmler C, von Spiczak S, Kroemer HK, Runge U, Boor R, Stephani U, Cascorbi I: Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics. 2009 May;19(5):353-62. [PubMed:19415824 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:39